Drug Profile

UB iC200

Alternative Names: UB-iC200

Latest Information Update: 19 Jul 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Umoja Biopharma
Class Antineoplastics; Gene therapies
Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity; Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

19 Jul 2023 Discontinued - Preclinical for Solid tumours in USA (Parenteral)
11 Oct 2022 Umoja Biopharma plans an IND application in US for Solid tumours in 2024(Umoja Biopharma pipeline; October 2022)
01 Oct 2022 Preclinical trials in Solid tumours in USA (Parenteral)(Umoja Biopharma pipeline; October 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com